Across two continents and two entirely different biological pathways to disease, a single AI-powered blood test has proven it can find liver cancer early — a quiet but consequential step in medicine's long effort to catch what kills before it becomes unstoppable. Researchers at Johns Hopkins have validated the DELFI platform using cell-free DNA analysis in populations from Guatemala and Romania, demonstrating that molecular fingerprints of cancer transcend geography, genetics, and cause. The test does not merely detect disease; it reads the biological story surrounding it, drawing signals from